Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the CaribbeanBusiness Wire • 09/15/26
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/14/26
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 09/08/26
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of MedicinesBusiness Wire • 09/08/26
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?The Motley Fool • 09/05/26
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?24/7 Wall Street • 09/04/26
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 09/01/26
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?Zacks Investment Research • 09/01/26
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV InfectionZacks Investment Research • 08/28/26
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsCNBC • 08/27/26
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex RegimensBusiness Wire • 08/27/26
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor ConferencesBusiness Wire • 08/26/26
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy LiftingThe Motley Fool • 08/26/26
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBCZacks Investment Research • 08/25/26
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 StatusBusiness Wire • 08/24/26
Robbins LLP Encourages ITOC Stockholders Who Lost Money Investing in iTonic Holdings Ltd. to Contact the Firm for Information About Leading the Class ActionNewsfile Corp • 08/19/26